Kymbee (deflazacort) NDC 0245-0813

NDC codes

FDA NDC Directory

Product NDC (as listed)0245-0813Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00245-0813Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0245-0813-13	00245081313	1 BOTTLE in 1 CARTON (0245-0813-13) / 13 mL in 1 BOTTLEMarketed from Jun 5, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Kymbee
Generic name (nonproprietary): deflazacort
Active ingredients: Deflazacort — 22.75 mg/mL
Dosage form: Suspension
Route: Oral
Labeler: Upsher-Smith Laboratories, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216992
Marketing start: Jun 5, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 0245-0813_548be9b3-be2c-7d81-e063-6394a90a8793SPL ID 548be9b3-be2c-7d81-e063-6394a90a8793SPL set ID ba749cfb-813d-4799-9e7b-44ede92065f2RxCUI 1870964, 2745410UNII KR5YZ6AE4B
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400245081313 followed by a unit qualifier and the quantity

Package 00245-0813-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 18, 2026.

Indications (excerpt from the label)

KYMBEE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. KYMBEE is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)